Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$14.3M
Filings
195
Firms Hired
6
Active Period
2012–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · fourth_quarter · Firm: THE WASHINGTON TAX & PUBLIC POLICY GROUP
Issues related to corporate and international taxation. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 951A, 250, and 174. (H.R. 1990, S. 1649, H.R. 1 - Sections - 70321, 70322, 70323, 70302)
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1
American Innovation and R&D Competitiveness Act of 2025
2025 · fourth_quarter · Firm: THE WASHINGTON TAX & PUBLIC POLICY GROUP
Issues related to corporate and international taxation. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 951A, 250, and 174. (H.R. 1990, S. 1649, H.R. 1 - Sections - 70321, 70322, 70323, 70302)
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1990
Sporting Goods Excise Tax Modernization Act
2025 · fourth_quarter · Firm: THE WASHINGTON TAX & PUBLIC POLICY GROUP
Issues related to corporate and international taxation. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 951A, 250, and 174. (H.R. 1990, S. 1649, H.R. 1 - Sections - 70321, 70322, 70323, 70302)
Client expense: — · Firm income: $30,000
Matched citations: S. 1649
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · third_quarter · Firm: THE WASHINGTON TAX & PUBLIC POLICY GROUP
Issues related to corporate and international taxation. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 951A, 250, 162(m), and 174. (H.R. 1990, S. 1649, H.R. 1 - Sections - 70321, 70322, 70323, 70302, 70604)
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1
American Innovation and R&D Competitiveness Act of 2025
2025 · third_quarter · Firm: THE WASHINGTON TAX & PUBLIC POLICY GROUP
Issues related to corporate and international taxation. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 951A, 250, 162(m), and 174. (H.R. 1990, S. 1649, H.R. 1 - Sections - 70321, 70322, 70323, 70302, 70604)
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1990
Sporting Goods Excise Tax Modernization Act
2025 · third_quarter · Firm: THE WASHINGTON TAX & PUBLIC POLICY GROUP
Issues related to corporate and international taxation. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 951A, 250, 162(m), and 174. (H.R. 1990, S. 1649, H.R. 1 - Sections - 70321, 70322, 70323, 70302, 70604)
Client expense: — · Firm income: $30,000
Matched citations: S. 1649
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · second_quarter · Firm: THE WASHINGTON TAX & PUBLIC POLICY GROUP
Issues related to corporate and international taxation. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 951A, 250, 162(m), and 174. (H.R. 1990, S. 1649, H.R. 1 - Sections - 70321, 70322, 70323, 70302, 70604)
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1
American Innovation and R&D Competitiveness Act of 2025
2025 · second_quarter · Firm: THE WASHINGTON TAX & PUBLIC POLICY GROUP
Issues related to corporate and international taxation. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 951A, 250, 162(m), and 174. (H.R. 1990, S. 1649, H.R. 1 - Sections - 70321, 70322, 70323, 70302, 70604)
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1990
Sporting Goods Excise Tax Modernization Act
2025 · second_quarter · Firm: THE WASHINGTON TAX & PUBLIC POLICY GROUP
Issues related to corporate and international taxation. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 951A, 250, 162(m), and 174. (H.R. 1990, S. 1649, H.R. 1 - Sections - 70321, 70322, 70323, 70302, 70604)
Client expense: — · Firm income: $30,000
Matched citations: S. 1649
American Innovation and R&D Competitiveness Act of 2025
2025 · first_quarter · Firm: THE WASHINGTON TAX & PUBLIC POLICY GROUP
Issues related to corporate and international taxation. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 951A, 250, 162(m), 174 and 41. (H.R. 1990)
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1990
National Defense Authorization Act for Fiscal Year 2024
2024 · fourth_quarter · Firm: REGENERON PHARMACEUTICALS, INC.
Biodefense, FDA, national security, and privacy issues relating to biopharmaceutical manufacturers; Tax and incentives; Issues related to drug manufacturing and pricing; H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024; Issues relating to pandemic preparedness and infectious disease education; Issues relating to utilization management; Issues relating to health care extenders; Issues related to federal contracting relating to biopharmaceutical manufacturers
Client expense: $400,000 · Firm income: —
Matched citations: H.R. 2670
National Defense Authorization Act for Fiscal Year 2024
2024 · third_quarter · Firm: REGENERON PHARMACEUTICALS, INC.
Biodefense, FDA, national security, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024; issues relating to pandemic preparedness and infectious disease education; issues relating to utilization management; issues relating to health care extenders; issues related to federal contracting relating to biopharmaceutical manufacturers
Client expense: $400,000 · Firm income: —
Matched citations: H.R. 2670
National Defense Authorization Act for Fiscal Year 2024
2024 · second_quarter · Firm: REGENERON PHARMACEUTICALS, INC.
Biodefense, FDA, national security, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024; issues relating to pandemic preparedness and infectious disease education; issues relating to step therapy; issues relating to health care extenders; issues related to federal contracting relating to biopharmaceutical manufacturers
Client expense: $400,000 · Firm income: —
Matched citations: H.R. 2670
National Defense Authorization Act for Fiscal Year 2024
2024 · first_quarter · Firm: REGENERON PHARMACEUTICALS, INC.
Biodefense, FDA, national security, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024; issues relating to pandemic preparedness and infectious disease education; issues relating to step therapy; issues relating to health care extenders; issues related to federal contracting relating to biopharmaceutical manufacturers
Client expense: $430,000 · Firm income: —
Matched citations: H.R. 2670
EPA Accountability to Farm Country Act
2023 · fourth_quarter · Firm: REGENERON PHARMACEUTICALS, INC.
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; issues relating to the Inflation Reduction Act; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; issues relating to the Prescription Drug User Fee Act; issues relating to infectious disease education; issues relating to the Pandemic and All-Hazards Preparedness reauthorization; Biomedical Advanced Research and Development Authority contract; issues relating to step therapy; issues relating to development of COVID therapeutics; issues relating to health care extenders
Client expense: $430,000 · Firm income: —
Matched citations: H.R.7900
EPA Accountability to Farm Country Act
2023 · third_quarter · Firm: REGENERON PHARMACEUTICALS, INC.
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; issues relating to the Inflation Reduction Act; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; issues relating to the Prescription Drug User Fee Act; issues relating to infectious disease education; issues relating to the Pandemic and All-Hazards Preparedness reauthorization; Biomedical Advanced Research and Development Authority contract; issues relating to step therapy
Client expense: $400,000 · Firm income: —
Matched citations: H.R.7900
Affordable Insulin Now Act of 2023
2023 · third_quarter · Firm: REGENERON PHARMACEUTICALS, INC.
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; issues relating to the Inflation Reduction Act; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; issues relating to the Prescription Drug User Fee Act; issues relating to infectious disease education; issues relating to the Pandemic and All-Hazards Preparedness reauthorization; Biomedical Advanced Research and Development Authority contract; issues relating to step therapy
Client expense: $400,000 · Firm income: —
Matched citations: S.954
EPA Accountability to Farm Country Act
2023 · second_quarter · Firm: REGENERON PHARMACEUTICALS, INC.
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; issues relating to the Inflation Reduction Act; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; issues relating to the Prescription Drug User Fee Act; issues relating to infectious disease education; issues relating to the Pandemic and All-Hazards Preparedness reauthorization; issues relating to step therapy
Client expense: $370,000 · Firm income: —
Matched citations: H.R.7900
Affordable Insulin Now Act of 2023
2023 · second_quarter · Firm: REGENERON PHARMACEUTICALS, INC.
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; issues relating to the Inflation Reduction Act; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; issues relating to the Prescription Drug User Fee Act; issues relating to infectious disease education; issues relating to the Pandemic and All-Hazards Preparedness reauthorization; issues relating to step therapy
Client expense: $370,000 · Firm income: —
Matched citations: S.954
Inflation Reduction Act of 2022
2023 · first_quarter · Firm: REGENERON PHARMACEUTICALS, INC.
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; Consolidated Appropriations Act, 2023; issues related to the Prescription Drug User Fee Act
Client expense: $460,000 · Firm income: —
Matched citations: H.R.5376
EPA Accountability to Farm Country Act
2023 · first_quarter · Firm: REGENERON PHARMACEUTICALS, INC.
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; Consolidated Appropriations Act, 2023; issues related to the Prescription Drug User Fee Act
Client expense: $460,000 · Firm income: —
Matched citations: H.R.7900
Affordable Insulin Now Act of 2023
2023 · first_quarter · Firm: REGENERON PHARMACEUTICALS, INC.
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; Consolidated Appropriations Act, 2023; issues related to the Prescription Drug User Fee Act
Client expense: $460,000 · Firm income: —
Matched citations: S.954
Inflation Reduction Act of 2022
2022 · fourth_quarter · Firm: REGENERON PHARMACEUTICALS, INC.
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022; S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats, (PREVENT) and Pandemics Act; Consolidated Appropriations Act, 2023
Client expense: $320,000 · Firm income: —
Matched citations: H.R.5376
Food and Drug Amendments of 2022
2022 · fourth_quarter · Firm: REGENERON PHARMACEUTICALS, INC.
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022; S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats, (PREVENT) and Pandemics Act; Consolidated Appropriations Act, 2023
Client expense: $320,000 · Firm income: —
Matched citations: H.R.7667
National Defense Authorization Act for Fiscal Year 2023
2022 · fourth_quarter · Firm: REGENERON PHARMACEUTICALS, INC.
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022; S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats, (PREVENT) and Pandemics Act; Consolidated Appropriations Act, 2023
Client expense: $320,000 · Firm income: —
Matched citations: H.R.7900
Source: Senate LDA